Development of Engineered T Cells Expressing a Chimeric CD16-CD3 zeta Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

导出原文传递

翻译打印收藏纠错

作者： Tanaka, Hiroki ^[1] ; Fujiwara, Hiroshi ^[2] ; Ochi, Fumihiro ^[3] ; Tanimoto, Kazushi ^[4] ; Casey, Nicholas ^[5] ; Okamoto, Sachiko ^[6] ; Mineno, Junichi ^[7] ; Kuzushima, Kiyotaka ; Shiku, Hiroshi ; Sugiyama, Takashi ; Barrett, A. John ; Yasukawa, Masaki

作者单位： Takara Bio Inc, CDM Ctr, Otsu, Shiga, Japan ^[1] Mie Univ, Grad Sch Med, Dept Canc Vaccine & Immunogene Therapy, Tsu, Mie, Japan ^[2] Ehime Univ, Grad Sch Med, Dept Obstet & Gynecol, Toon, Ehime, Japan ^[3] Ehime Univ, Grad Sch Med, Dept Hematol Clin Immunol & Infect Dis, Toon, Ehime, Japan ^[4] Ehime Univ, Grad Sch Med, Dept Pediat, Toon, Ehime, Japan ^[5] NHLBI, Hematol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA ^[6] Aichi Canc Ctr, Div Immunol, Nagoya, Aichi, Japan ^[7]

发布时间 2017-05-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical cancer research

2016年22卷17期

4405-4416页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Development of Engineered T Cells Expressing a Chimeric CD16-CD3 zeta Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Development of Engineered T Cells Expressing a Chimeric CD16-CD3 zeta Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除